Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

AstraZeneca

Status and phase

Completed

Phase 3

Conditions

Schizophrenia

Treatments

Drug: Quetiapine Fumarate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00085891

D1444C00133

Details and patient eligibility

About

The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient is able to provide written informed consent before beginning any study related procedures
Patient has a documented clinical diagnosis of schizophrenia
Patient is able to understand and comply with the requirements of the study, as judged by a study investigator

Exclusion criteria

Patients with a history of non-compliance as judged by the study investigator
Patients with a known lack of response to previous treatment with quetiapine
Patients who have participated in another drug study within 4 weeks prior to enrollment into this study
Patients who have previously participated in this study or study D1444C00132